key: cord-0040357-1hzevodw
authors: van der Loeff, Maarten F. Schim
title: Epidemiology, Natural History and Treatment of HIV-2 Infections
date: 2009-05-15
journal: Global HIV/AIDS Medicine
DOI: 10.1016/b978-1-4160-2882-6.50060-5
sha: 0fb8f9e52a416542c8337367901e38616d762b29
doc_id: 40357
cord_uid: 1hzevodw

nan

In 1986, 3 years after the discovery of HIV-1, another retrovirus was identifi ed, and named HIV-2. 1,2 It was isolated from West African patients with AIDS and its discovery caused concern that another devastating epidemic was at hand. Quite soon, it was shown that HIV-2 is less transmissible, is characterized by slower disease progression, and is geographically limited to West Africa and countries with direct ties to that region. The probable explanation of the epidemiological differences is that the plasma viral load in HIV-2 infected persons tends to be much lower than in HIV-1 infected persons. [3] [4] [5] [6] In this chapter, the epidemiology, natural history, interactions with HIV-1, and treatment of HIV-2 are discussed. The comparison with HIV-1 is central to this chapter (see Table 56 .1). 

The transmission routes of HIV-2 are the same as for HIV-1: vaginal intercourse, anal intercourse, motherto-child transmission, blood transfusion, parenteral (e.g. needle-stick incidents, needle sharing among intravenous drug users). 7 The effi ciency of heterosexual transmission of HIV-2 is about 1 / 3 -1 / 4 that of HIV-1. 33, 8 This can be explained by the generally lower plasma viral load, but no data have been published to prove this. Heterosexual intercourse is thought to account for the large majority of HIV-2 infections worldwide.

The prevalence of HIV-2 exceeds 5% in the adult general population in only one country, Guinea-Bissau. 34 In other West African countries the prevalence in the general population is usually around 1 or 2%. Among high-risk groups higher prevalences have been observed (e.g. among female commercial sex workers: 38% in Southern Senegal, 35 27 .5% in The Gambia, 36 41% in Abidjan, Cote d'Ivoire). 37 Outside West Africa, the infection is found in Portugal (the former colonial power in Guinea-Bissau), where 4% of AIDS cases are caused by HIV-2, and sporadically elsewhere in Europe. [38] [39] [40] [41] In the USA, only one case of HIV-2 infection was detected among 7 000 000 blood donors over a 4-year period (1997-2000) . 42 Sporadic cases of HIV-2 have also been detected in Asia (e.g. India, Korea) and South America (e.g. Brazil).

All repeated cross-sectional studies from West African countries have shown stable or declining prevalences of HIV-2; this was the case in diverse populations like female commercial sex workers, 33, 36, 37, [43] [44] [45] [46] an occupational cohort, 34 pregnant women, 34, 37, [47] [48] [49] STD patients, 50,51,51A and the general population. 52 There are very few studies reporting incidence rates of HIV-2. In a peri-urban community in Guinea-Bissau the incidence was 0.5 per 100 person-years of observation (pyo); 53 among female commercial sex workers in Dakar the incidence rate was 1.1 per 100 pyo. 33 Three cohort studies reported incidence rates over different time periods; among commercial sex workers in Dakar the incidence was stable 33 and in an occupational cohort and in a peri-urban 7 40 000 000 2 000 000 a Transmission routes 7 Heterosexual, homosexual, Same mother-to-child, blood transfusions, needle sharing/ incidents Mother-to-child-transmission 4 20-40% 3, 5, 14, 19 Usually high: 10 000-100 000 Usually low: undetectable to 1000 copies/ml copies/ml; 1 / 3 -1 / 5 of subjects have undetectable PVL Proviral load (in asymptomatic Similar Similar subjects) 13, 14, 16, 24, 25 Use of co-receptors 21 CCR5 and CXCR4 Broader: CCR5 and CXCR4 and several others Sensitive to NNRTI 20 Yes No Immunological CD4 decline 14, 26 Fast Slow Immune activation 27, 28 High Low Neutralizing antibodies Effi cient, broad specifi city Less effi cient, narrow specifi city CTL 29, 30, 31 Common, mostly against gag Same Apoptosis of T cells 27, 32 High community in Bissau the rates were falling over time in men and stable in women. 34, 52 Because all studies report stable or declining incidences and prevalences in West Africa, and no new HIV-2 epidemics have been observed outside West Africa, HIV-2 should not be considered an emergent epidemic, but an epidemic in decline.

In striking contrast to HIV-1, the highest prevalence of HIV-2 is not observed in young adults (15 to 34 years) but in older adults. This is the case in all study populations, whether female commercial sex workers, clinic patients, pregnant women or the general population. HIV-2 infection is very rare in children, even in Guinea-Bissau. The higher prevalence among older people could be the result of a cohort effect (lifelong infection with low mortality), or of an increased susceptibility of older persons, especially women. 54, 55 The low prevalence among children is due to the very low mother-to-child transmission rate of 4%, which again can be attributed to the lower plasma viral load in HIV-2-infected pregnant women. 4

The trend of a declining epidemic raises one of the fundamental, still unanswered questions about HIV-2: which events created the epidemic, and what has changed so that the epidemic is no longer sustained? HIV-2 is genetically indistinguishable from the simian immunodefi ciency virus of the sooty mangabey (SIV sm ) 56 monkey. The natural habitat of the sooty mangabey (Cercocebus torquatus atys) is West Africa. Based on the large degree of genetic homology, the geographic overlap, and the fact that human-monkey contacts are common in West Africa, most researchers maintain that SIV sm is the source of HIV-2. 57 In a phylogenetic tree, most subtypes of HIV-2 cluster closer to specifi c strains of SIV sm than to each other. 58, 59 Therefore it is assumed that the eight different clades of HIV-2 9-11 represent at least eight different zoonotic events.

HIV-1 is thought to originate from chimpanzee SIV (SIV cpz ); the exact details of this zoonotic event are unknown and are controversial. 60, 61 Back-calculations using mutation rates of the viral genome as a molecular clock have estimated the timing of the original transmission from chimpanzee to human at about 1930. 62, 63 In analogy to HIV-1, these back-calculations have recently been done for HIV-2. Based on partial sequences of 33 samples, the most likely date of the zoonotic event giving rise to the HIV-2 subtype A epidemic was estimated to be 1940 (± 16 years). 12 Assuming that one person or a few persons became infected with HIV-2 clade A through contact with a sooty mangabey, it is still unclear how this led to an epidemic. It is theoretically possible that the virus used to be more virulent than it is now, but this is unlikely: there is no record of an epidemic of an AIDS-like syndrome in West Africa prior to 1985. So, if we assume that the virulence of the virus has not substantially changed over time, there must have been an increase in transmission that amplifi ed a small outbreak into a large epidemic. This could have been due to an increase in unscreened blood transfusions on a large scale, high rates of sexual partner change, many concurrent sexual partnerships or presence of co-factors enhancing sexual transmission like sexually transmitted infections (STIs), or non-sterile injections. Several of these factors may have been present at the same time in Guinea-Bissau, especially in the period from 1963 to 1974, when a war of independence was fought against Portugal. The transmission of the virus may not be effi cient enough to maintain ongoing epidemic spread in the absence of important amplifi ers such as frequent commercial sex, high levels of STIs, and unscreened blood transfusions.

Marx hypothesized that re-use of unsterilized needles may have been responsible for both the HIV-1 and HIV-2 epidemics. 57 In West Africa, various mass vaccination and treatment campaigns against yaws, yellow fever, and small pox were conducted in the fi nal decades of the colonial era, 64 and these may have been responsible for mass inoculations with HIV-2. There is no proof for this and it does not explain why HIV-2 became epidemic in Guinea-Bissau and nowhere else.

HIV-2 infection can lead to disease manifestations, including AIDS, that are similar to those seen in HIV-1 infection. Not all infected persons progress to clinical disease, and the extent of non-progressors is not known. In Senegal 85% of HIV-2 infected women in a sero-incident cohort remained free of disease 8 years later. 65, 66 In Guinea-Bissau, several persons aged over 80 years were HIV-2 infected and symptomfree; the date of infection in these octogenarians is uncertain but is presumed to be some decades ago. There are case reports of persons who have been infected 20 years or more without clinical signs and symptoms.

Although the average progression to symptomatic disease and premature death is much slower in Natural History HIV-compared with HIV-1, fast disease progression does occur. 40 Once patients have a CD4 count below 200 cells/μL 67 or they have AIDS 67A , the mortality rate is similar to that in HIV-1. In The Gambia, the median time to death after AIDS was 12.6 months. This was signifi cantly longer than that of HIV-1 infected patients, and the difference was attributed to the higher CD4 count at time of AIDS in HIV-2 compared with HIV-1 infected patients. 67A As in HIV-1 infection, lower CD4 counts are associated with symptomatic HIV-2 infection and mortality. The CD4 count is an independent predictor of mortality. 67 In a clinic-based study in The Gambia the mortality rate among HIV-2 infected women with CD4 count ≥500 cells/μL was 8.1 per 100 pyo; in those with CD4 counts between 200 and 500 cells/μL it was 18.4 per 100 pyo; and among those with CD4 count <200 cells/μL it was 83.6 per 100 pyo. 67 Also in community-based studies from The Gambia and Guinea-Bissau 5,6,13 mortality rates were signifi cantly higher in the groups with lower CD4 counts. In the clinic-based study from The Gambia the mortality rates were similar between HIV-1 and HIV-2 infected patients with CD4 counts below 200 cells/μL, but were signifi cantly lower for HIV-2 infected patients compared to HIV-1 infected patients in the group with CD4 cell counts ≥500 cells/μL. 67

The plasma viral load (PVL) in HIV-2 infected persons tends to be much lower than in HIV-1 infection. 3, 4, 14 In a community-based sample of 130 HIV-2 infected persons in rural Guinea-Bissau, the median PVL was only 347 copies/mL. 5 In a cross-sectional clinic-based study in The Gambia, 17 of 23 asymptomatic patients (74%) had undetectable PVL. 3 In the latter study it was also shown that the PVL varied with disease stage. Among patients with CD4% >28%, the median PVL was 460 copies/mL; among those with CD4% between 14% and 28%, the median PVL was 28 000 copies/mL; and among those with CD4% <14% the median PVL was 65 000 copies/mL. 3 In a clinic-based study in Senegal, plasma viral load predicted CD4 decline in HIV-2, like in HIV-1 infection. The annual rate of decline of the CD4 count among asymptomatic HIV-2 patients was 1 / 4 that of asymptomatic HIV-1 patients (4.1% versus 15.9%). 14 The difference in loss of CD4 cells could be attributed to the lower plasma viral load in HIV-2 infected patients, and was not determined by the HIV type per se. 14 HIV-2 plasma viral load is an independent and strong predictor of mortality. 5, 6, 15 In a communitybased study in Guinea-Bissau, the mortality rate among HIV-2 infected persons rose 1.7 times (95% Confi dence Interval 1.2-2.3, P = 0.002) for each log 10 increase of virus copies/mL. 5 In a study among women recruited during pregnancy in The Gambia, the mortality rate among infected persons with undetectable PVL and normal CD4% was not significantly different from that of women without HIV infection. 6 In a multivariate analysis, PVL and CD4 count were independent predictors of mortality, but HIV type (HIV-1 or HIV-2) was not. 6 Another possibility is that in HIV-1 infection, more DNA is integrated and replication-competent compared with HIV-2. It is also possible that in HIV-1 infection, high proviral DNA levels exist in other compartments than blood. Finally, it may be that HIV-2 virions are cleared more effi ciently. 14 In six long-term non-progressing HIV-2 infected patients with undetectable plasma viral load and normal CD4 counts, it could be demonstrated that replication-competent virus was present in peripheral blood mononuclear cells (PBMCs), albeit at extremely low concentrations. 69

Although clinical AIDS in HIV-2 is similar to that in HIV-1, a few differences have been observed. Despite a similar prevalence of HHV8 infection, HIV-2 infected subjects had a much lower incidence of Kaposi's sarcoma in a study from The Gambia. 17 An autopsy study from Cote d'Ivoire found that HIV-2 infected patients were more likely to have severe multi-organ cytomegalovirus (CMV) infection, HIV encephalitis, and cholangitis than HIV-1 infected patients, suggesting a more prolonged terminal disease course. 70 Tuberculosis (TB) is a major opportunistic infection for HIV-2 infected patients, and its incidence increases strongly with decreasing CD4 counts. 71 In a clinic-based study from The Gambia, no difference in TB incidence was observed between HIV-1-and HIV-2-infected persons with similar CD4 counts. A study among hospital patients in Dakar found that chronic diarrhea and diarrhea caused by bacterial infections were more frequent in HIV-2 compared with HIV-1-infected patients with AIDS; oral candidiasis and chronic fever were more frequent in HIV-1 patients with AIDS. 72 The median CD4 count among HIV-2 patients with AIDS varied between 73 and 358 cells/μL in several studies from West Africa and Paris. 39, 67A,72-75 In a clinic-based study in The Gambia, the median CD4 count at the time of AIDS diagnosis was 176 cells/μL in HIV-2 patients (n = 87), which was significantly higher than the 109 cells/μL in HIV-1 patients (n = 341). 67A The median CD4 count near the time of death was found to be between 61 and 146 cells/μL in HIV-2 infected patients. 67A,70,76 This is higher than the usual CD4 count at time of death reported from HIV-1 infection, but most studies on HIV-1 were done in developed countries with better end-of-life care than in most of Africa.

One of the fi rst epidemiological studies on HIV-2, conducted in Bissau in 1987-1988, 77 showed that the mortality associated with HIV-2 infection was much lower than that usually found in HIV-1 infection. All subsequent studies have confi rmed this. 5, 6, 53, 67, 73, 78 In a seroprevalent clinical cohort in The Gambia, HIV-2 patients had a lower mortality than HIV-1 patients, but this lower mortality was limited to those with a normal CD4 count (>500/μL). Among those with a CD4 count <200/μL, the mortality rate was similar between HIV-1-and HIV-2-infected subjects. 67 This could be explained in two ways. The fi rst possibility is that all HIV-2-infected subjects experience a deterioration of their immune system, but this decline is slower than in HIV-1 infection. Once the CD4 count has declined to below 200/μL, patients are at high risk of fatal opportunistic infections and there is no difference in mortality. The other possibility is that those with HIV-2 infection fall in either of two categories: those whose immune system is not affected at all by the infection, and those whose immune system is damaged by the infection, at a rate similar to HIV-1. This question is unresolved and long-term follow-up of an incident cohort would be required to answer it.

HIV-2 infection in children is rare, even in endemic areas, due to the low mother-to-child transmission risk of 4%. 4 There are few data on the clinical course of HIV-2 in children. In the only prospective longterm observational study of children with perinatally acquired HIV infection (median follow-up time 6.6 years), conducted in The Gambia, three out of eight HIV-2 infected children died (38%) compared with 12 out of 17 HIV-1 infected children (71%) and 40 out of 448 children of HIV-uninfected mothers (9%). The mortality rate of HIV-2-infected children was signifi cantly higher than that of uninfected children (P = 0.02), but the difference with HIV-1-infected children did not reach statistical signifi cance (P = 0.08). 79

Using type-specifi c antibody tests, it became evident that both HIV-1 and HIV-2 circulated in West Africa. Samples of some people in West Africa showed dual serological reactivity, and it was not clear whether this was mainly due to antibody cross-reactivity, dual infection, or an infection with a third, unknown virus. 80 Quite early on, it was demonstrated by PCR that dual infection with both HIV-1 and HIV-2 did occur. 81, 82 Later improvements in PCR techniques showed that a large proportion of people with dually reactive samples (up to 86%) is truly dually infected. 83, 84 

In 1995, Travers and co-workers 85 reported that HIV-2 seemed to offer protection against subsequent HIV-1 infection in a cohort of commercial sex workers in Dakar; this caused excitement and hope as it could lead to the development of a vaccine against HIV-1. 18 Several research groups in Guinea-Bissau, 34, 86 Cote d'Ivoire, 87, 88 and The Gambia 89,90 examined this putative effect in other cohorts. None of the seven analyses so far have been able to reproduce this fi nding, so currently available epidemiological data do not support a protective effect of HIV-2 infection against incident HIV-1 infection. 91 The investigators of the cohort in which the original fi nding was made, have provided no updates of the effect in that cohort since 1999, 66, 92, 93 so it is unknown whether the effect in that cohort persisted, or declined over time, or even reversed. Two studies compared the distribution of HIV-1 subtypes among singly infected and HIV-1 and HIV-2 dually infected subjects, and found no differences in frequencies. 94, 95 This argues against a possible protective effect of HIV-2 that is limited to certain HIV-1 subtypes.

Two cross-sectional studies from West Africa have examined the pattern of PVL and CD4 count in dually infected patients. In these studies it was found that in patients with low CD4 counts, the PVL of HIV-1 is very high and that of HIV-2 very low. 96, 97 This contrasts with singly infected HIV-2 patients with low CD4 counts, in whom the PVL tends to be high. 3, 96 In dually infected patients with normal CD4 counts, the PVL of HIV-2 tended to be comparable with that in singly HIV-2 infected subjects. In all CD4 strata, the PVL of HIV-1 appeared similar to that in HIV-1-singly infected subjects. 96 This suggests that in patients with progressing immunodefi ciency, HIV-1 is out-competing HIV-2, and that the disease progression is dictated by HIV-1 rather than HIV-2.

There is only one long-term study analyzing the survival and mortality of subjects with dual HIV infection. 67 Among patients of the genito-urinary (GU) clinic in Fajara, The Gambia, the mortality rate of 107 dually infected patients was similar to that of HIV-1-infected patients, and worse than that of HIV-2-infected patients. This was true overall, and after adjusting for baseline CD4 count. These data do not support suggestions that HIV-2 infection could mitigate the course of HIV-1 infection.

If a person is infected with two or more subtypes of HIV-1, these can re-combine their genomes to form new strains of HIV-1, and these can be transmitted. Some of the recombinant strains are successful in spreading, e.g. CRF01_AE in Thailand and CRF02_ AG in West Africa. 98 Recombinations of the genetically rather distant groups O and M have been described, 99-101 but so far no recombinations of HIV-1 and HIV-2 have been reported. Construction of chimeric HIV-1/SIV viruses indicate that this is biologically possible. 102, 103 Curlin and co-workers 104 searched for recombinations in the env gene of 46 dually infected patients in Senegal, but found none. It is possible that these recombinations are very rare or that their productive existence is constrained by biological factors. 104

As PVL and CD4 count are key predictors of disease progression in both HIV-1 and HIV-2, 5,6,14,15 it appears logical to use the same principles in their treatment. The mortality rate of HIV-2 infected subjects with undetectable PVL and normal CD4 count is not increased compared with uninfected people, 6 and these people may never need treatment. Randomized controlled clinical trials for treatment of HIV-2 infection have not been done, and at the time of writing, there are no agreed international treatment guidelines specifi c to HIV-2. Available clinical data are case reports, 105,106 case series, 41, 39, 107 and cohorts. 108, 109 The suggestions for treatment given here are based on the few available clinical data, on in vitro studies, and on extrapolation of what is known from treatment of HIV-1 infection.

ART should be started when the patient has AIDS. Symptomatic, non-AIDS, disease should not be an indication for treatment, as the symptoms or conditions may be unrelated to HIV-2. This is especially important in sub-Saharan Africa, where the background incidence of HIV-associated conditions is relatively high. 110 Patients with a CD4 count <200 cells/μL should be started on ART. For those with a CD4 count between 200 and 350 cells/μL, ART should be considered, and those with CD4 counts above 350 cells/μL should be monitored but treatment could be deferred (Table 56. 2).

The objective of treatment should be to reduce the PVL to undetectable levels. As there is no commercially available plasma viral load assay, it will be diffi cult in practice to monitor PVL outside specialized research centers where in-house assays have been developed. 3, 14, 19, [111] [112] [113] Therefore monitoring of When plasma viral load is high (e.g. >10 000 copies/mL), there is more reason to start ART than when plasma viral load is low. ART, antiviral therapy.

CD4 count may be the only option, but this will be showing treatment failure at a later stage than monitoring plasma viral load.

HIV-2 is inherently resistant to the non-nucleoside analog reverse transcriptase inhibitor (NNRTI) class of drugs. 20, [114] [115] [116] The virus can become resistant to nucleoside-analog reverse transcriptase inhibitors (NRTIs) and to protease inhibitors (PIs). 41, 117 Although no data are available, it is assumed that adherence is as crucial in HIV-2 as in HIV-1 to prevent resistance formation and maintain suppression of plasma viral load. In recent years, resistance mutations in HIV-2 have been identifi ed, but the interpretation of genotypic resistance data in HIV-2 is diffi cult and no agreed guidelines exist. [118] [119] [120] Some mutations appear to have the same signifi cance as in HIV-1 infection (e.g. M184V conferring resistance against lamivudine and Q151M conferring resistance against NRTIs), 108,109,121 but other mutations may have an impact different to that in HIV-1. 118,119

Although overall, HIV-2 is a less virulent virus than HIV-1, patients that have progressing infection, with HIV-associated symptoms, high PVL, and decreasing CD4 count, have a poor prognosis, similar to HIV-1 infected patients. 6, 67 Therefore they should be treated as vigorously as HIV-1-infected patients, with at least three drugs. NNRTIs are not active against HIV-2. 20, [114] [115] [116] NRTIs and PIs are effective, although clinical studies suggested that nelfi navir is less effective against HIV-2 than against HIV-1. 41, 108, 109 Amprenavir and atazanavir are not active against HIV-2 in vitro. 20, 116 In in vitro studies, HIV-2 strains appeared to be naturally resistant against the fusion inhibitor enfuvirtide. 116 This means that there are far fewer therapeutic options for HIV-2 patients. A fi rst option could be a combination of two NRTIs and a boosted PI, e.g. indinavir or lopinavir. 109 The choice of a salvage regimen will be even more restricted than in HIV-1. 109,119

There are no data showing the long-term benefi ts of ART in HIV-2. A study of 18 ARV treated patients in Cote d'Ivoire showed a doubling of the CD4 count after 12 months of treatment, from 82 to 163 cells/μL, but this was not statistically signifi cant. 108 In The Netherlands, 11 out of 13 HIV-2-infected patients treated with ZDV-3TC-IND/RTV had successful suppression of plasma viral load during the entire course of treatment (median duration 91 weeks, range 52-234 weeks). The CD4 count increased from a median 90 cells/μL to a median 270 cells/μL. 109

Some patients are infected with both HIV-1 and HIV-2 and in West Africa this is not uncommon. 67 In these patients HIV-1 is the virus that dictates disease progression, with low HIV-2 PVL and high HIV-1 PVL. 96, 97 This has led some researchers to advocate that treatment should be directed against HIV-1 only. 97 This may be dangerous as exemplifi ed by a patient whose HIV-1 PVL was successfully suppressed, but who nevertheless progressed due to unsuppressed HIV-2 PVL. 122 Therefore, drugs should be chosen that cover both infections, so NNRTIs, some PIs (e.g. nelfi navir and amprenavir), and enfuvirtide should be avoided. 20, 116 

Mortality among children with HIV-2 is higher than in seronegative children and this suggests that children with HIV-2 infection need the same care as HIV-1-infected children. There are no published data from clinical trials or even cohort studies or patient series that could guide the treatment of HIV-2-infected children. The same principles as in treatment of HIV-1infected children should guide the management of pediatric HIV-2 infection, with the caveat about the choice of antiretroviral drugs mentioned above.

HIV-2 is an infection of public health interest in West Africa, where up to 2 million people may be infected; an unknown proportion of these will suffer from HIV-2 induced immunodefi ciency and premature mortality. Antiretroviral treatment is effective against HIV-2, but no evidence-based guidelines for treatment exist. It is suggested that principles and guidelines for treatment of HIV-1 are used, while avoiding the use of NNRTIs, which are not effective against HIV-2, some protease inhibitors (amprenavir, nelfi navir), and enfuvirtide. HIV-2 is a human model for HIV-1 infection and elucidation of its lower pathogenicity may provide clues for an effective vaccine against HIV-1. 21 

There are four crucial questions regarding HIV-2 that are unanswered. The fi rst question is: Why did a zoonotic event lead to a localized HIV-2 epidemic in Guinea-Bissau and why is this epidemic now in decline? In recent decades, several animal pathogens jumped the species barrier and caused epidemics in humans (among others: HIV-1, HIV-2, the corona virus causing SARS, Ebola virus, prions causing variant Creutzfeldt-Jakob disease). In the case of HIV-1 and HIV-2, some widely discussed hypotheses have held medical interventions responsible for the epidemics. It seems important to trace the origin of these epidemics, whether that means confi rming or rejecting these hypotheses. Phylogenetic analyses on a larger scale than have been done so far, and epidemic modeling studies that try to fi t the existing data, can contribute to answering this question.

The second question is: What proportion of people that are HIV-2-infected develop immunodefi ciency or AIDS, and die prematurely? This proportion needs to be known to better understand the pathogenesis of HIV-2 infection, to inform patients about their prognosis, and to help identify factors that may determine non-progression. Estimates based on prevalent cohorts are biased; long-term follow-up of seroconverters is needed to answer this question. There are few such cohorts and all are small; collaboration between research groups in West Africa could help to answer this question.

The third question is: Why does HIV-2 infection usually not lead to high plasma viral loads, in spite of proviral loads similar to HIV-1? This could be due to characteristics inherent to the virus, or to a more effi cient immune response, or to generally lower levels of immune activation. This question could be examined by detailed comparative virological and immunological studies.

The fi nal unanswered question: Is the virological, immunological, and clinical response of HIV-2 infected people to highly active antiretroviral therapy similar to that in HIV-1-infected people? The fi rst observational data are suggesting this is the case. In order to establish effective, evidence-based treatment regimens for HIV-2 disease, clinical trials and cohort studies of antiretroviral therapy should be conducted in HIV-2-infected patients.

Molecular cloning and polymorphism of the human immune defi ciency virus type 2

Lymphadenopathy-associated virus type 2 in AIDS and AIDS-related complex. Clinical and virological features in four patients

Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection

Maternal plasma viral RNA levels determine marked differences in mother-to-child transmission rates of HIV-1 and HIV-2 in The Gambia. MRC/Gambia Government/University College London Medical School working group on mother-child transmission of HIV

Low level viremia and high CD4% predict normal survival in a cohort of HIV type-2-infected villagers

Contrasts in plasma viral load, CD4% and survival in a community-based cohort of HIV-1 and HIV-2 infected women in The Gambia

Towards a better understanding of the epidemiology of HIV-2 (review)

Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal

Human immunodefi ciency virus type 2 (HIV-2) seroprevalence and characterization of a distinct HIV-2 genetic subtype from the natural range of simian immunodefi ciency virusinfected sooty mangabeys

Identifi cation of a new HIV-2 subtype based on phylogenetic analysis of fulllength genomic sequence

Identifi cation of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classifi cation

Tracing the origin and history of the HIV-2 epidemic

A community-based study of human immunodefi ciency virus type 2 provirus load in a rural village in West Africa

Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodefi ciency virus (HIV) type 1-and type 2-infected individuals from Senegal, West Africa

Plasma RNA viral load predicts the rate of CD4 T cell decline and death in HIV-2 infected patients in West Africa

HIV type 2 proviral load measured by quantitative polymerase chain reaction correlates with CD4+ lymphopenia in HIV type 2-infected individuals

Kaposi's Sarcoma in the Gambia, West Africa is less frequent in Human Immunodefi ciency Virus type 2 than in Human Immunodefi ciency Virus type 1 infection despite a high prevalence of Human Herpes virus 8

Can one type of HIV protect against another type? (News; Comment)

Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in

Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV

Human immunodefi ciency virus type-2, an AIDS virus with two faces

HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries?

Genetic diversity of human immunodefi ciency virus type 2: evidence for distinct sequence subtypes with differences in virus biology

Quantitation of human immunodefi ciency virus type 2 DNA in peripheral blood mononuclear cells by using a quantitativecompetitive PCR assay

Plasma RNA viral load in human immunodefi ciency virus type 2 subtype A and subtype B infections

Rate of decline of percentage CD4+ cells is faster in HIV-1 than in HIV-2 infection

Reduced immune activation and T cell apoptosis in human immunodefi ciency virus type 2 compared with type 1: correlation of T cell apoptosis with beta2 microglobulin concentration and disease evolution

CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load

Comparison of human immunodefi ciency virus (HIV)-specifi c T-cell responses in HIV-1-and HIV-2-infected individuals in Senegal

HIV-2 and T cell recognition

No differences in cellular immune responses between asymptomatic human immunodefi ciency type 1 and type 2-infected Gambian patients

HIV type 2 primary isolates induce a lower degree of apoptosis 'in vitro' compared with HIV type 1 primary isolates

Slower heterosexual spread of HIV-2 than HIV-1

Trends and interaction of HIV-1 and HIV-2 in Guinea-Bissau, west Africa: no protection of HIV-2 against HIV-1 infection

Prevalence and risk determinants of human immunodefi ciency virus type 2 (HIV-2) and human immunodefi ciency virus type 1 (HIV-1) in west African female prostitutes

Asymptomatic carriage of Haemophilus ducreyi confi rmed by the polymerase chain reaction

Trends in the HIV-1 and HIV-2 epidemics in Abidjan, Cote d'Ivoire: 11 years of HIV serosurveillance at Project Retro-CI. Abstract B041

Human immunodefi ciency virus type 2 infection in Spain. The HIV-2 Spanish Study Group

Factors associated with clinical progression in HIV-2 infected-patients: The French ANRS cohort

HIV-2 infection in 12 European residents: virus characteristics and disease progression

Antiretroviral therapy for HIV-2 infected patients

Two percent of HIVpositive U. S. blood donors are infected with non-subtype B strains

HIV-2 infection among prostitutes working in The Gambia: association with serological evidence of genital ulcer diseases and with generalized lymphadenopathy

HIV-2-induced immunosuppression among asymptomatic West African prostitutes: evidence that HIV-2 is pathogenic, but less so than HIV-1

Trends in HIV-1 and HIV-2 infection in The Gambia

Genetic subtypes of HIV type 1 and HIV type 2 strains in commercial sex workers from Bamako, Mali

Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic

The epidemic of HIV/AIDS in Abidjan, Cote d'Ivoire: a review of data collected by Projet RETRO-CI from 1987 to 1993

Regional differences in HIV trends in The Gambia: results from sentinel surveillance among pregnant women

Human retroviral infections in The Gambia: prevalence and clinical features

Association between HIV-2 infection and genital ulcer diseases among male sexually transmitted disease patients in The Gambia

Sixteen years of HIV surveillance in a West African research clinic reveals divergent epidemic trends of HIV-1 and HIV-2

Declining HIV-2 prevalence and incidence among men in a community study from Guinea-Bissau

9-year HIV-2-associated mortality in an urban community in Bissau, west Africa

Age of wife as a major determinant of male-to-female transmission of HIV-2 infection: a community study from rural West Africa

Increased prevalence of retrovirus infections among older women in Africa

An African primate lentivirus (SIVsm) closely related to HIV-2

Serial human passage of simian immunodefi ciency virus by unsterile injections and the mergence of epidemic human immunodefi ciency virus in Africa

Human infection by genetically diverse SIVsm-related HIV-2 in West Africa

Genetic characterization of new West African simian immunodefi ciency virus SIVsm: geographic clustering of household-derived SIV strains with human immunodefi ciency virus type 2 subtypes and genetically diverse viruses from a single feral sooty mangabey troop

The river: a journey back to the source of HIV and AIDS

Natural and iatrogenic factors in human immunodefi ciency virus transmission

Timing the ancestor of the HIV-1 pandemic strains

Using human immunodefi ciency virus type 1 sequences to infer historical features of the acquired immunodefi ciency syndrome epidemic and human immunodefi ciency virus evolution

The control of endemic treponematoses

Reduced rate of disease development after HIV-2 infection as compared to HIV-1

Human Immunodefi ciency Virus Type 2 (HIV-2)

Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in The Gambia

Is HIV-2 induced AIDS different from HIV-1 associated AIDS? Data from a West African clinic

Low plasma human immunodefi ciency virus type 2 viral load is independent of proviral load: low virus production in vivo

HIV-2-infected individuals with undetectable plasma viremia carry replication-competent virus in peripheral blood lymphocytes

The mortality and pathology of HIV infection in a West African city

Incidence of tuberculosis and survival after its diagnosis in patients infected with HIV-1 and HIV-2

AIDS caused by HIV1 and HIV2 infection: are there clinical differences? Results of AIDS surveillance 1986-97 at Fann Hospital in Dakar

Clinical features, immunological changes and mortality in a cohort of HIV-2

Clinical and laboratory predictors of survival in Gambian patients with symptomatic HIV-1 or HIV-2 infection

HIV-2 and HIV-1 AIDS cases in Senegal: clinical patterns and immunological perturbations

HIV-1 and HIV-2 AIDS in African patients living in Paris (letter)

Prevalence of and mortality from human immunodefi ciency virus type 2 in Bissau, West Africa

The effects of HIV-2 infection in a rural area of Guinea-Bissau

Survival of HIV-1 and HIV-2 perinatally infected children in The Gambia

HIV-1 and HIV-2 infections and AIDS in West Africa

Simultaneous isolation of HIV-1 and HIV-2 from an AIDS patient

Mixed human immunodefi ciency virus (HIV) infection in an individual: demonstration of both HIV type 1 and type 2 proviral sequences by using polymerase chain reaction

Improved detection of HIV-2 proviral DNA in dually seroreactive individuals by PCR

High concordance between polymerase chain reaction and antibody testing of specimens from individuals dually infected with HIV types 1 and 2 in Guinea-Bissau

Natural protection against HIV-1 infection provided by HIV-2

Does HIV-2 protect against HIV-1 infection? (letter)

Lack of protection against HIV-1 infection among women with HIV-2 infection

Effect of interventions to control sexually transmitted disease on the incidence of HIV infection in female sex workers

Does HIV-2 infection provide cross-protection against HIV-1 infection? (letter)

HIV-2 does not protect against HIV-1 infection in a rural community in Guinea-Bissau

Possible protective effect of HIV-2 against incident HIV-1 infection: review of available epidemiological and in vitro data

HIV-2 and natural protection against HIV-1 infection

HIV-2 provides natural protection against HIV-1 infection

Molecular characterization of human immunodefi ciency virus (HIV)-1 and -2 in individuals from Guinea-Bissau with single or dual infections: predominance of a distinct HIV-1 subtype A/G recombinant in West Africa

Molecular epidemiology of dual HIV-1/HIV-2 seropositive adults from Senegal, West Africa

Plasma viral load, CD4% and survival of HIV-1, HIV-2, and dually infected Gambian patients

Differences in HIV-2 plasma viral load and immune activation in HIV-1 and HIV-2 dually infected persons and those infected with HIV-2 only in Abidjan

Understanding the genetic diversity of HIV-1

Triple HIV-1 infection with group O and group M of different clades in a single Cameroon patient

Human immunodefi ciency virus type 1 intergroup (M/O) recombination in Cameroon

Characterisation of a highly replicative intergroup M/O human immunodefi ciency virus type I recombinant isolated from a Cameroonian patient

Generation and characterization of infectious chimeric clones between human immunodefi ciency virus type 1 and simian immunodefi ciency virus from an African green monkey

Construction of human immunodefi ciency virus 1/simian immunodefi ciency virus strain mac chimeric viruses having vpr and/or nef of different parental origins and their in vitro and in vivo replication

No evidence for recombination between HIV type 1 and HIV type 2 within the envelope region in dually seropositive individuals from Senegal

Immunologic and virologic response of HIV-2 infection to antiretroviral therapy

Rapid progression of CD4 cell decline and subsequent response to salvage therapy in HIV-2 infection

Highly active antiretroviral therapy and viral response in HIV type 2 infection

Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profi les of patients treated in

Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients

Progression to symptomatic disease in people infected with HIV-1 in rural Uganda: prospective cohort study

Development of a real-time quantitative RT-PCR for the detection of HIV-2 RNA in plasma

Human immunodefi ciency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load

Lower human immunodefi ciency virus (HIV) type 2 viral load refl ects the difference in pathogenicity of HIV-1 and HIV-2

Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiretroviral drugs and drug combinations

Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV

Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis

Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy

High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen

HIV antiretroviral drug resistance in Africa

Protease Gene and Selection of Drug Resistance Mutations in HIV-2-Infected Patients Treated with Protease Inhibitors

Emergence of drug resistance mutations in human immunodefi ciency virus type 2-infected subjects undergoing antiretroviral therapy

Antiretroviral therapy in patients with dual infection with human immunodefi ciency virus types 1 and 2

I would like to thank Hilton Whittle, Koya Ariyoshi and Andreas Hansmann for their comments on a draft of this chapter.